Daratumumab Confirmed as SOC for AL AmyloidosisDecember 17, 2024Multiple MyelomaBleeding DisordersMixed TopicsASH 2024
Multiple Myeloma: Dexamethasone-Sparing Approach Benefits Frail Older AdultsDecember 13, 2024Multiple MyelomaPatient & Survivor CareASH 2024
New Cancer Drugs: Do Patients Prefer Faster Access or Clinical Benefit?December 12, 2024Patient & Survivor CareMixed TopicsDLBCLBusiness of MedicineAggressive LymphomasAMLALL
24-Hour Urine Testing in Multiple Myeloma: Time to Stop?December 9, 2024Multiple MyelomaPatient & Survivor CareASH 2024
IVIG Prophylaxis in Multiple Myeloma Cuts Infections, Boosts SurvivalDecember 9, 2024Multiple MyelomaASH 2024
Inside the Patient-Oncologist Bond: Why It’s Often So StrongDecember 2, 2024Patient & Survivor CareMixed TopicsDLBCLMultiple MyelomaAMLAggressive LymphomasALL
ASH 2024 Myeloma Studies: My Top 10 PicksNovember 22, 2024Multiple MyelomaCellular TherapyPatient & Survivor Care
Outpatient CAR T: Safe, Effective, AccessibleNovember 4, 2024Cellular TherapyB Cell LymphomaMantle Cell LymphomaMultiple MyelomaMixed TopicsBusiness of MedicinePatient & Survivor Care
Multi-Refractory MM: After Immunotherapy, What?October 25, 2024Multiple MyelomaGene TherapyCellular Therapy
For Radiation ‘Downwinders,’ Cancer Compensation Is On HoldOctober 25, 2024Patient & Survivor CareNon-Hodgkin LymphomaMultiple MyelomaDLBCLCMLALLAML
